Both lung lesions were surgically resected, followed by adjuvant chemotherapy with ifosfamide and doxorubicin. This case emphasizes that even histologically benign-appearing prostatic SFTs can demonstrate malignant potential. It also underscores the necessity of long-term surveillance and contributes to the literature by reporting the first known case of a metastatic SFT originating from the prostate gland.

In May 2025, the patient initiated intravenous chemotherapy consisting of pegylated liposomal doxorubicin and ifosfamide. This case highlights the importance of early integration of histopathological and molecular evaluation for progressive thyroid lesions. The co-occurrence of NF1 and BCORL1 mutations, along with TP53 and TERT promoter alterations, may underlie the tumor's aggressive biological behavior and supports the incorporation of molecular subtyping strategies in TLS management.

AI therapy is useful for advanced or recurrent MPTs. The observed clinical benefit of pazopanib in a patient with FGFR1 N546K-mutated MPT suggests that FGFR1 kinase domain mutations may be a relevant factor in responsiveness of FGFR1-targeted therapy. Further data accumulation is warranted.

The anti-inflammatory effects indicate the IL-1β - COX-1 - PGE2 axis may be putatively directly or indirectly deactivated by FC. All findings have actually suggested FC is safer if orally introduced and strongly support its effectiveness, whose pharmacological use relies on time of exposure, dose, frequency, and route.

Introducing zoledronate (ZOL) to OS cells augments γδ T cell killing by upregulating phosphoantigens in treated cells, which induces butyrophilin complexes, which are recognized by the TCR of the γδ T cell and significantly increases target cell death in both control and TGF-β expanded γδ T cells. In addition, administering ifosfamide (IFO), a chemotherapy used for relapsed OS, induces stress antigens in OS cell lines that are recognized by NKG2D receptors on γδ T cells, which enhances γδ T cell killing. In vivo studies show the administration of TGF-β expanded γδ T cells, when combined with ZOL and IFO significantly increased overall survival in OS-bearing mice, which we show can be attributed, at least in part, to increased persistence compared to control cells. Together, these data demonstrate this chemoimmunotherapy strategy, which engages various targeting mechanisms of γδ T cells, significantly enhances killing of OS.

The patient underwent 4 courses of chemotherapy with ifosfamide and pirarubicin. The findings from this case highlight the morphologic and immunohistochemical features that are diagnostic of this rare uterine tumor. Furthermore, this report summarizes the morphologic criteria for malignancy and the key points for its differential diagnosis.

P2, N=12, Terminated, Alaunos Therapeutics | The SRC reduced 140 mg to 100 mg, then to 80 mg. The study ended with one subject enrolled at 80 mg daily.

P2, N=148, Recruiting, HRYZ Biotech Co. | Not yet recruiting --> Recruiting

She received six cycles of ifosfamide and doxorubicin, followed by a second excision, which showed persistent tumor activity. Both surgery and chemotherapy have been shown to enhance outcomes. Ongoing monitoring is crucial, and additional research on MEK inhibitors and genetic profiling is imperative for tailoring treatment strategies.

Adjuvant radiotherapy was given to 35.64 % of patients, and chemotherapy (doxorubicin + ifosfamide) was administered to those with metastases. While variables such as age, gender, tumor size, surgical margin status, and NF1 status exhibited varying correlations, the most accurate predictors of survival were tumor biology, namely histological grade and metastatic occurrence.The cornerstone of curative treatment continues to be postoperative radiation after wide local excision with negative surgical margins. The results highlight the necessity of aggressive care and early detection, particularly in high-grade or NF1-associated patients.

P2, N=24, Recruiting, Swiss Group for Clinical Cancer Research | Not yet recruiting --> Recruiting

This study represents a significant advancement in drug modification as a potential chemotherapeutic strategy for endometrial cancer. Among the two modified drugs, altered 5-fluorouracil demonstrated superior binding affinity and pharmacokinetic properties, rendering it a promising candidate.